The National Health Insurance Civilian Surveillance Alliance yesterday questioned the legitimacy of a certification for pharmaceutical manufacturers after a majority of the manufacturers that were required by the Food and Drug Administration (FDA) to re-file bioequivalence testing (BE) reports for changes made to their products were awarded PIC/S GMP or GMP certification.
BE testing is conducted to ensure that a generic drug delivers the same therapeutic effect as a reference brand-name pharmaceutical.
In response, the agency said that the changes to the drugs were “legitimate” and have no negative impact on drug safety.
Photo: Wei Yi-chia, Taipei Times
At the end of August, the health insurance watchdog held a press conference to report that as many as 3,841 drug products failed to comply with pharmaceutical regulations after making changes to package inserts, packaging and the excipients used in drugs without seeking re-approval by the regulator.
In response, the agency promised to hold risk assessment meetings to evaluate the drugs that had been altered.
This month, the agency announced that 33 out of 3,841 generic drug products would need to be tested for their bioequivalence with brand-name medicines, with 21 more to be examined.
The group found that 10 of the 11 drug manufacturers that produce the 33 drugs are PIC/S GMP (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, or the guide to Good Manufacturing Practice for medicinal products) or GMP certified.
“The government has required all pharmaceutical manufacturers to be PIC/S-certified by the end of next year, after which those without will not be permitted to make or sell drugs in Taiwan,” alliance spokeswoman Eva Teng (滕西華) said.
“However, the 10 manufacturers account for 15.8 percent of the 57 PIC/S GMP-certified manufacturers in the country. This makes us concerned that the certification does not guarantee drug quality,” Teng added.
The lack of BE testing reports for drugs that have been altered is a major problem, the group said.
“Changing the excipient, the diluent or the vehicle of a drug could decrease its therapeutic effect,” alliance convener Huang Sue-ying (黃淑英) said, adding that the agency should have ordered that the 33 drug products be pulled off shelves immediately after the announcement this month.
“The agency asked doctors to look for substitutes as soon as possible, and said that the drugs were without health risks,” she said.
FDA official Chi Jo-feng (祁若鳳) said that the PIC/S GMP certificate would not be revoked unless the violations are “grave,” such as producing counterfeit drugs, adding that the drugs were not withdrawn from the market immediately because some patients need time to switch to a new drug.
The agency updated the list in a statement yesterday, announcing the final result of the assessment for the need of BE testing on a total of 54 drugs (including the 33 announced earlier), which said that only nine of the 54 would need to redo BE testing.
One of the 33 drugs required to be tested this month was made exempt because the manufacturer had subsequently handed in relevant documents, while several others decided to revert to the original formula or simply give up the permit for the drug and had their products pulled off shelves, an FDA official said.
Hong Kong singer Eason Chan’s (陳奕迅) concerts in Kaohsiung this weekend have been postponed after he was diagnosed with Covid-19 this morning, the organizer said today. Chan’s “FEAR and DREAMS” concert which was scheduled to be held in the coming three days at the Kaohsiung Arena would be rescheduled to May 29, 30 and 31, while the three shows scheduled over the next weekend, from May 23 to 25, would be held as usual, Universal Music said in a statement. Ticket holders can apply for a full refund or attend the postponed concerts with the same seating, the organizer said. Refund arrangements would
Taiwanese indie band Sunset Rollercoaster and South Korean outfit Hyukoh collectively received the most nominations at this year’s Golden Melody Awards, earning a total of seven nods from the jury on Wednesday. The bands collaborated on their 2024 album AAA, which received nominations for best band, best album producer, best album design and best vocal album recording. “Young Man,” a single from the album, earned nominations for song of the year and best music video, while another track, “Antenna,” also received a best music video nomination. Late Hong Kong-American singer Khalil Fong (方大同) was named the jury award winner for his 2024 album
Palauan President Surangel Whipps Jr arrived in Taiwan last night to kick off his first visit to the country since beginning his second term earlier this year. After arriving at Taoyuan International Airport at around 6:30 pm, Whipps and his delegation were welcomed by Minister of Foreign Affairs Lin Chia-lung (林佳龍). Speaking to gathered media, the Palauan leader said he was excited and honored to be back in Taiwan on his first state visit to Taiwan since he was sworn in this January. Among those traveling with Whipps is Minister of State Gustav N. Aitaro, Public Infrastructure
Premier Cho Jung-tai (卓榮泰) on Friday laid out the Cabinet’s updated policy agenda and recapped the government’s achievements ahead of the one-year anniversary of President William Lai’s (賴清德) inauguration. Cho said the government had made progress across a range of areas, including rebuilding Hualien, cracking down on fraud, improving pedestrian safety and promoting economic growth. “I hope the public will not have the impression that the Cabinet only asked the legislature to reconsider a bunch of legal amendments,” Cho said, calling the moves “necessary” to protect constitutional governance and the public’s interest. The Cabinet would work toward achieving its “1+7” plan, he said. The